Key Highlights

  • 22nd Century Group (NASDAQ:XXII) traded at USD 0.1424, up 61.09%, in pre-market trading on Tuesday, October 27, 2026, after an expanded Pinnacle Pure range, with preliminary third quarter revenue of about USD 4.8 million.
  • Farmmi (NASDAQ:FAMI) traded at USD 0.1120, up 8.42%, with no dated announcement, a net loss of USD 53,385,988 for the year ended September 30, 2025 and an offering priced at USD 0.25 per share.
  • Cyabra (NASDAQ:CYAB) traded at USD 0.1420, up 7.09%, on record second quarter revenue of USD 1.9 million, while VivoSim Labs (NASDAQ:VIVS) traded at USD 0.1597, up 5.07%, with cash of about USD 10.1 million.
  • The shared driver is price level: at quotes below USD 0.20, small orders move the price sharply, and each name also carries dilution risk. All quotes are thin pre-market snapshots.

22nd Century Group (NASDAQ:XXII): the only name with a dated trigger

22nd Century Group (NASDAQ:XXII), a tobacco products company that markets the Pinnacle VLN and Pinnacle Pure brands, traded at USD 0.1424 in pre-market trading, a gain of 61.09% in the snapshot. The company's release of Monday, October 26, 2026 expanded Pinnacle Pure to six variants, adding 100's-size and Menthol (Green) varieties, with shipments expected from December 2026. The move appears consistent with a reaction to these two announcements, although the company has not linked either to the share price.

For the quarter ended Wednesday, September 30, 2026, unaudited revenue from continuing operations was about USD 4.8 million, up 66% from USD 2.9 million in the second quarter. Gross profit was about USD 0.4 million, against a gross loss of USD 0.3 million, and the net loss was about USD 2.6 million. Cash fell to about USD 3.9 million from USD 6.1 million. The improving gross margin supplies the mechanism for the reaction, while the cash balance sets its limit.

The bull reading rests on a 161% rise in same-store unit sales of its brands at the launch retail partner, which operates about 1,500 outlets. The bear reading rests on a net loss more than six times gross profit, by simple arithmetic, and on an unfinalised proposed nicotine standard of 0.70 mg/g. The full third-quarter report is due on or before Friday, November 13, 2026.

Farmmi (NASDAQ:FAMI): a listing clock running at the lowest quote of the four

Farmmi, Inc. (NASDAQ:FAMI), a Cayman Islands holding company with operating subsidiaries in mainland China, historically focused on edible fungi products, traded at USD 0.1120 in the pre-market snapshot. No company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the move. Market capitalisation was about USD 4.2 million, according to market data, so the gain appears consistent with thin liquidity, an inference.

The annual report on Form 20-F for the year ended September 30, 2025 showed revenue of USD 27,971,360, against USD 64,131,332 in fiscal 2024. The company priced an underwritten offering of 12,000,000 Class A shares and pre-funded warrants at USD 0.25 on Monday, June 29, 2026, raising about USD 3.0 million gross, so the quote is about 55% below that price, by simple arithmetic. A framework agreement of Tuesday, August 4, 2026 for a Brazilian acquisition is payable in Class A shares.

A Nasdaq notice of Tuesday, August 11, 2026 set a compliance period to Monday, February 8, 2027 under Listing Rule 5550(a)(2), which needs a close at or above USD 1.00 for 10 consecutive business days. The bear reading is that revenue more than halved, and a reverse split or share-based consideration could dilute holders.

Cyabra (NASDAQ:CYAB): growth set against a small market value

Cyabra (NASDAQ:CYAB), a company selling artificial intelligence software that detects disinformation, impersonation and influence campaigns, traded at USD 0.1420 in the pre-market snapshot. No announcement dated Monday, October 26, 2026 or Tuesday, October 27, 2026 accompanied the move; the latest, of Wednesday, October 21, 2026, named it a Sample Vendor, meaning a representative provider, in 10 Gartner Hype Cycle reports. The move appears consistent with continued interest after October contract announcements and with thin liquidity, both inferences.

The company's release of Thursday, August 13, 2026 reported second quarter revenue of USD 1.9 million, up 39% from USD 1.3 million, with gross profit of about USD 1.5 million, a margin of about 84%. The net loss was about USD 3.4 million, against USD 2.4 million a year earlier, and the release noted a USD 6.0 million private placement. October brought a multi-award contract position with the FBI, whose five-year ordering period runs through September 2031.

The bull reading rests on revenue growth, margin and that federal pipeline. The bear reading rests on a quarterly net loss set against a market value of about USD 3.75 million per market data, which implies repeated financing needs, and on contract positions that do not guarantee orders. No listing notice was identified in the releases reviewed.

VivoSim Labs (NASDAQ:VIVS): cash cover and a rapidly expanding share count

VivoSim Labs (NASDAQ:VIVS), a San Diego based company that tests drug candidates in three-dimensional human tissue models, traded at USD 0.1597 in the pre-market snapshot. No company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the move. The most recent disclosure reviewed is the Form 8-K of Thursday, August 6, 2026. The advance appears consistent with thin liquidity, an inference.

For the fiscal first quarter ended June 30, 2026, revenue was USD 18,000 and the net loss was USD 1.3 million, or USD 0.25 per share. The release stated cash of approximately USD 10.1 million, reflecting a USD 5.0 million milestone payment from Eli Lilly and Company on Wednesday, July 22, 2026 and a financing of Friday, July 17, 2026 with gross proceeds of USD 4.0 million at USD 0.85 per underlying share.

The bull reading rests on cash against the quarterly loss and a target of fiscal 2027 revenue growth above 500%, measured from a very small base. The bear reading rests on dilution: shares outstanding rose from 3,194,295 to 13,390,789 between June 30 and August 3, 2026, and the quote sits well below the financing price, by simple arithmetic.

Where Things Stand

The answer is that a sub-USD 0.20 price amplifies whatever the fundamentals offer, but the gains differ in quality. 22nd Century Group (NASDAQ:XXII) has dated product and revenue news behind its rise, while Farmmi (NASDAQ:FAMI), Cyabra (NASDAQ:CYAB) and VivoSim Labs (NASDAQ:VIVS) rose without a dated trigger, and each pairs a small market value or low quote with a financing history. A price this low also puts the Nasdaq minimum bid price standard of USD 1.00 in view for every name, although only Farmmi has a notice in the filings reviewed.

The next catalysts are the Federal Reserve decision on Wednesday, October 28, 2026, the 22nd Century third-quarter report due on or before Friday, November 13, 2026 and the Farmmi compliance deadline of Monday, February 8, 2027. Pre-market prices are snapshots and can change before the open at 9:30 a.m. ET, and this is not investment advice.